CO7131359A2 - Agentes de imagen para detectar disfunción neurológica - Google Patents

Agentes de imagen para detectar disfunción neurológica

Info

Publication number
CO7131359A2
CO7131359A2 CO14255692A CO14255692A CO7131359A2 CO 7131359 A2 CO7131359 A2 CO 7131359A2 CO 14255692 A CO14255692 A CO 14255692A CO 14255692 A CO14255692 A CO 14255692A CO 7131359 A2 CO7131359 A2 CO 7131359A2
Authority
CO
Colombia
Prior art keywords
compound
mammal
brain tissue
imaging agents
neurological dysfunction
Prior art date
Application number
CO14255692A
Other languages
English (en)
Spanish (es)
Inventor
Anna Katrin Szardenings
Hartmuth C Kolb
Joseph C Walsh
Gang Chen
Umesh B Gangadharmath
Dhanalakshmi Kasi
Changhui Lui
Anjana Sinha
Eric Wang
Chul Yu
Wei Zhang
Kai Chen
Vani P Mocharla
Peter J Scott
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/477,095 external-priority patent/US8932557B2/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO7131359A2 publication Critical patent/CO7131359A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/18—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
CO14255692A 2012-05-22 2014-11-20 Agentes de imagen para detectar disfunción neurológica CO7131359A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13/477,095 US8932557B2 (en) 2008-02-14 2012-05-22 Imaging agents for detecting neurological dysfunction

Publications (1)

Publication Number Publication Date
CO7131359A2 true CO7131359A2 (es) 2014-12-01

Family

ID=47146722

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14255692A CO7131359A2 (es) 2012-05-22 2014-11-20 Agentes de imagen para detectar disfunción neurológica

Country Status (9)

Country Link
EP (1) EP2852572B1 (cg-RX-API-DMAC7.html)
JP (1) JP5976206B2 (cg-RX-API-DMAC7.html)
KR (1) KR101609504B1 (cg-RX-API-DMAC7.html)
CN (2) CN104781234A (cg-RX-API-DMAC7.html)
AU (1) AU2012381042B2 (cg-RX-API-DMAC7.html)
CA (1) CA2873963C (cg-RX-API-DMAC7.html)
CO (1) CO7131359A2 (cg-RX-API-DMAC7.html)
ES (1) ES2792830T3 (cg-RX-API-DMAC7.html)
WO (1) WO2013176698A1 (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10662193B2 (en) * 2014-01-21 2020-05-26 Ac Immune Sa Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyloid-like proteins
CA2946446C (en) * 2014-04-22 2020-11-03 Universite De Montreal Pyrido-pyrrolo-pyrimidine and pyrido-indole compounds, pharmaceutical compositions containing same and their use thereof in the expansion of hematopoietic stem cells and/or hematopoietic progenitor cells
MX376163B (es) 2014-05-13 2025-03-07 Hoffmann La Roche Compuestos heterocíclicos deuterados y su uso como agentes formadores de imágenes.
US20180022748A1 (en) * 2015-02-02 2018-01-25 Ucb Biopharma Sprl 9h-pyrrolo-dipyridine derivatives
US10080812B2 (en) 2015-03-04 2018-09-25 Kyoto University Radioactive iodine labeled pyrido[1,2-a]benzoimidazole derivative compound
TW201707726A (zh) 2015-08-19 2017-03-01 國立大學法人京都大學 放射性鹵素標誌吡啶并[1,2-a]苯并咪唑衍生物化合物
ES2864825T3 (es) 2015-11-13 2021-10-14 Lilly Co Eli Derivados de azetidina para la obtención de imágenes Tau
EP3487545A1 (en) 2016-07-22 2019-05-29 AC Immune S.A. Compounds for imaging tau protein aggregates
WO2018015549A1 (en) 2016-07-22 2018-01-25 Ac Immune S.A. Compounds for imaging tau protein aggregates
WO2018024643A1 (en) 2016-08-02 2018-02-08 Ucb Biopharma Sprl 9h-pyrrolo-dipyridine derivatives
WO2018024642A1 (en) 2016-08-02 2018-02-08 Ucb Biopharma Sprl 9h-pyrrolo-dipyridine derivatives
MX2019005007A (es) * 2016-11-01 2019-07-18 Arvinas Inc Protac dirigidos a la proteína tau y métodos asociados de uso.
CN109884194A (zh) * 2017-12-06 2019-06-14 新疆维吾尔药业有限责任公司 一种药用植物的分离方法及其产品和应用
WO2019145291A1 (en) 2018-01-24 2019-08-01 Ac Immune Sa Gamma-carboline compounds for the detection of tau aggregates
EP3743426A1 (en) 2018-01-24 2020-12-02 AC Immune SA Azacarboline compounds for the detection of tau aggregates
CN108409634B (zh) * 2018-05-10 2021-04-27 曲阜师范大学 咔唑类荧光胺类化合物标记试剂、合成和应用
US11707452B2 (en) 2018-08-20 2023-07-25 Arvinas Operations, Inc. Modulators of alpha-synuclein proteolysis and associated methods of use
KR102215255B1 (ko) * 2019-06-12 2021-02-15 한국과학기술연구원 타우 응집체에 선택적으로 결합하는 형광 탐침자로서 유효한 신규 화합물 및 이의 제조 방법
EP3999182A1 (en) 2019-07-17 2022-05-25 Arvinas Operations, Inc. Tau-protein targeting compounds and associated methods of use
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
CN116003402B (zh) * 2021-11-02 2025-08-29 上海如絮生物科技有限公司 一种三环类化合物、其中间体、制备方法和应用
CN114539250B (zh) * 2022-03-04 2023-08-29 上海裕兰生物科技有限公司 一种阿尔兹海默症PET-tau示踪剂的制备方法
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
WO2024163546A1 (en) 2023-02-02 2024-08-08 Eli Lilly And Company Novel compounds for tau imaging
CN117050070B (zh) * 2023-07-05 2025-10-14 湘潭大学 一种荧光探针及其制备方法和在Aβ检测中的应用
WO2025155625A1 (en) 2024-01-16 2025-07-24 Eli Lilly And Company Novel compounds for tau imaging

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006005063A2 (en) * 2004-06-30 2006-01-12 Smithkline Beecham Corporation Methods and compositions
FR2885905A1 (fr) * 2005-05-23 2006-11-24 Trophos Sa Nouveaux composes chimiques et leurs utilisations comme medicament
DE102006062203A1 (de) * 2006-12-22 2008-06-26 Curacyte Discovery Gmbh Substituierte 5H-Pyrimido[5,4-b]indole als Induktoren der Apoptose bei B-CLL Zellen
WO2008132454A1 (en) * 2007-04-26 2008-11-06 Ge Healthcare Limited Carbolines and their use as imaging agents
EP2599763A1 (en) * 2008-02-14 2013-06-05 Siemens Molecular Imaging, Inc. Novel imaging agents for detecting neurological dysfunction
WO2010011964A2 (en) * 2008-07-24 2010-01-28 Siemens Medical Solutions Usa, Inc. Imaging agents useful for identifying ad pathology
JP2012051804A (ja) * 2008-12-26 2012-03-15 Kyoto Univ Eg5阻害剤
CN102438660A (zh) * 2009-03-23 2012-05-02 美国西门子医疗解决公司 用于检测神经障碍的显像剂
US8691187B2 (en) * 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
US10639608B2 (en) * 2010-04-08 2020-05-05 Siemens Medical Solutions Usa, Inc. System, device and method for preparing tracers and transferring materials during radiosynthesis
JP5585382B2 (ja) * 2010-10-22 2014-09-10 コニカミノルタ株式会社 有機エレクトロルミネッセンス素子、照明装置及び表示装置

Also Published As

Publication number Publication date
AU2012381042A1 (en) 2014-11-20
JP5976206B2 (ja) 2016-08-23
CA2873963A1 (en) 2013-11-28
EP2852572B1 (en) 2020-04-01
AU2012381042B2 (en) 2015-10-01
WO2013176698A1 (en) 2013-11-28
CN107011342A (zh) 2017-08-04
CA2873963C (en) 2017-04-11
ES2792830T3 (es) 2020-11-12
JP2015517572A (ja) 2015-06-22
EP2852572A1 (en) 2015-04-01
CN104781234A (zh) 2015-07-15
KR101609504B1 (ko) 2016-04-05
KR20150002854A (ko) 2015-01-07

Similar Documents

Publication Publication Date Title
CY1125258T1 (el) Νεοι παραγοντες απεικονισης για ανιχνευση νευρολογικης δυσλειτουργιας
Cohen et al. Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta
Mirzaei et al. In vivo imaging of microglial activation by positron emission tomography with [11C] PBR28 in the 5XFAD model of A lzheimer's disease
MX2016016384A (es) Pirrolo[2,3-c]piridinas como agentes de formacion de imagenes para ovillos neurofibrilares.
BR112014012822A8 (pt) Radioligantes rotulados com flúor-18 e carbono-11 para imagiologia por tomografia por emissão de pósitrons (pet) para lrrk2
Agosta et al. Neuroimaging findings in frontotemporal lobar degeneration spectrum of disorders
ECSP088645A (es) Nuevos benzotiazoles sustituidos con heteroaril
WO2010011964A3 (en) Imaging agents useful for identifying ad pathology
UA116774C2 (uk) Інгібітори серин/треонінкінази
MX375902B (es) Inhibidores de serina/treonina cinasa.
WO2009117728A3 (en) Compounds and compositions for the detection and treatment of alzheimer's disease and related disorders
EA201171397A1 (ru) Иммунологическое нацеливание на патологические тау-протеины
WO2011045415A3 (en) Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
BR112015025140A2 (pt) 2-fenilimidazo[1,2-a]pirimidinas como agentes de imagem
MX354662B (es) Anticuerpos fosfoespecificos que reconocen la tau.
MX2013012526A (es) Métodos para tratar la enfermedad de alzheimer, enfermedad de huntington, autismo u otros trastornos.
JP2014198718A5 (cg-RX-API-DMAC7.html)
Richter et al. The integrity of the cholinergic system determines memory performance in healthy elderly
AR114029A2 (es) Compuestos adecuados como precursores de compuestos que son útiles para obtener imágenes de depósitos amiloides, usos y procesos
BR112015027015A2 (pt) derivados de 2-fenil ou 2-hetaril imidazol[1,2-a]piridina
EP2734221A4 (en) METHOD FOR DIAGNOSIS AND TREATMENT OF ALZHEIMER DISEASE BY ADMINISTRATION OF AN ANGIOGENIC MEDIUM
Nobili et al. Radionuclide brain imaging correlates of cognitive impairment in Parkinson's disease (PD)
FR3049104B1 (fr) Procede de diagnostic de maladies inflammatoires chroniques de l'intestin
MX2009009113A (es) Nuevos indoles 2-heteroaril sustituidos 695.
Jansen et al. Assessment of cerebral dopamine D 2/3-receptors in patients with bilateral vestibular failure